Prognostic role of p53 gene polymorphism in risk assessment of anthracycline-induced cardiotoxicity

Aims. To study the prognostic significance of polymorphism of the p53 gene (polymorphism Arg72Pro exon 4, rs1042522) on the development of cardiotoxic remodeling of the left ventricle and heart failure. Material and methods. A total of 176 women with breast cancer who received anthracycline antibiotics as part of polychemotherapeutic treatment regimens were examined. Based on the results of the survey, 12 months after the end of polychemotherapy, patients in the remission of the underlying disease were divided into 2 groups: patients with cardiotoxic remodeling (52 patients) and women with preserved heart function (124 patients). All patients before the start of the course of chemotherapy, in the dynamics of treatment with anthracyclines and after therapy with such were carried out the study of echocardiographic parameters. All the patients were taken genetic material, followed by typing alleles of the gene for the protein p53 (rs1042522). Results. Analysis of echocardiographic parameters in patients 12 months after the completion of polychemotherapy in comparison with those before treatment showed a significant difference in the final systolic (33 mm [31; 35] and 28 mm [26; 31], p<0.00001) and terminal diastolic dimensions (51 mm [49; 54.5] and 44 mm [42; 48.5], p=0.0003), as well as a significant decrease in the left ventricular ejection fraction (54.5% [51.5; 58] and 65.5% [62; 70], p<0.00001) in the group of women with developed anthracycline cardiotoxicity. The presence of the Arg/Arg genotype was associated with the development of cardiotoxic myocardial damage during polychemotherapy (OR=3.86, 95% C.I.=1.45-10.26, p=0.005). The Pro/Pro genotype has proved to be a protective factor (OR=0.26, 95% C.I.=0.09-0.69, p=0.015). The conclusion. Predicting the cardiotoxicity of chemotherapy using the polymorphism of the p53 gene is an effective measure of early pre-symptom diagnosis of an increased risk of anthracyclineinduced cardiotoxicity.

cardiotoxicity, anthracyclines, apoptosis, heart failure, protein p53, genetic polymorphism

1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66(4):271–89. DOI: 10.3322/caac.21349

2. Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA et al. ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): Endorsed by the Heart Failure Society of America. Circulation. 2005;112(12):1853–87. DOI: 10.1161/CIRCULATIONAHA.105.170072

3. Seliverstova D.V., Evsina O.V. Cardiotoxicity of chemotherapy. Russian Heart Journal. 2016;15 (1):50–7. [Russian: Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце: журнал для практикующих врачей. 2016;15(1):50–7]. DOI: 10.18087/rhj.2016.1.2115

4. Vasyuk Yu.A., Shkolnik E.L., Nesvetov V.V., Shkolnik L.D., Varlan G.V. Cardiooncology: Current aspects of prevention of anthracycline toxicity. Kardiologiia. 2016;56 (12):72–9. [Russian: Васюк Ю.А., Школьник Е.Л., Несветов В.В., Школьник Л.Д., Варлан Г.В. Кардиоонкология: современные аспекты профилактики антрациклиновой кардиотоксичности. Кардиология. 2016; 56(12):72-9.]. DOI: 10.18565/cardio.2016.12.72-79

5. Vasyuk Yu.A., Shkolnik E.L., Nesvetov V.V., Shkolnik L.D., Selezneva M.G. Cardio-oncology: Current aspects in diagnostics for cardiovascular complications of antitumor therapy. Russian Heart Failure Journal. 2016;17 (6):383–7. [Russian: Васюк Ю.А., Школьник Е.Л., Несветов В.В., Школьник Л.Д., Селезнева М.Г. Кардиоонкология: современные аспекты диагностики сердечно-сосудистых осложнений при противоопухолевой терапии. Журнал Сердечная Недостаточность. 2016;17 (6):383–7.]. DOI: 10.18087/rhfj.2016.6.2327

6. Teplyakov A.T., Shilov S.N., Popova A.A., Grakova E.V., Berezikova E.N., Neupokoeva M.N. et al. The cardiovascular system in patients with anthracycline cardiomiopathy. Bulletin of Siberian Medicine. 2017;16 (3):127–36. [Russian: Тепляков А.Т., Шилов С.Н., Попова А.А., Гракова Е.В., Березикова Е.Н., Неупокоева М.Н. и др. Состояние сердечно-сосудистой системы у больных с антрациклиновой кардиомиопатией. Бюллетень сибирской медицины. 2017;16 (3):127–36]

7. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37 (36):2768–801. DOI: 10.1093/eurheartj/ehw211

8. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. The New England Journal of Medicine. 2000;342 (15):1077–84. DOI: 10.1056/NEJM200004133421502

9. Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2010;21 Suppl 5: v277–282. DOI: 10.1093/annonc/mdq200

10. Zhu W, Zhang W, Shou W, Field LJ. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity. Cardiovascular Research. 2014;103 (1):81–9. DOI: 10.1093/cvr/cvu118

11. Wang Y, Lei T, Yuan J, Wu Y, Shen X, Gao J et al. GCN2 deficiency ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and myocardial oxidative stress. Redox Biology. 2018;17:25–34. DOI: 10.1016/j.redox.2018.04.009

12. Kalyuzhin V. V., Teplyakov A.T., Vechersky Yu.Yu., Ryazantsevа N.V., Khlapov A.P. Pathogenesis of chronic heart failure: change of dominating paradigm. Bulletin of Siberian Medicine. 2007;6 (4):71–9. [Russian: Калюжин В.В., Тепляков А.Т., Вечерский Ю.Ю. Рязанцева Н.В., Хлапов А.П. Патогенез хронической сердечной недостаточности: изменение доминирующей парадигмы. Бюллетень сибирской медицины. 2007;6 (4):71–9]

13. Krotova Yu.N., Karkischenko V.N., Khloponin D.P. The role of apoptosis in myocardial pathology. Biomedicine. 2005;1:17–24. [Russian: Кротова Ю.Н., Каркищенко В.Н., Хлопонин Д.П. Роль апоптоза в патологии миокарда. Биомедицина. 2005;1:17–24]

14. Nepomnyashchikh L. M. Regenerative and plastic heart failure: molecular biological mechanisms and morphological bases. Archives of Pathology. 2007;69 (3):3–12. [Russian: Непомнящих Л. М. Регенераторно-пластическая недостаточность сердца: молекулярно-биологические механизмы и морфологические основы. Архив патологии. 2007;69 (3):3–12]

15. Green DR. The Pathophysiology of Mitochondrial Cell Death. Science. 2004;305 (5684):626–9. DOI: 10.1126/science.1099320

16. Uo T, Kinoshita Y, Morrison RS. Apoptotic Actions of p53 Require Transcriptional Activation of PUMA and Do Not Involve a Direct Mitochondrial/Cytoplasmic Site of Action in Postnatal Cortical Neurons. Journal of Neuroscience. 2007;27 (45):12198–210. DOI: 10.1523/JNEUROSCI.3222–05.2007

17. Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y et al. Transcriptional Blockade Induces p53-dependent Apoptosis Associated with Translocation of p53 to Mitochondria. Journal of Biological Chemistry. 2005;280 (19):19166–76. DOI: 10.1074/jbc.M410691200

18. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and Cellular Biology. 1999;19 (2):1092–100. DOI: 10.1128/mcb.19.2.1092

19. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-Dimensional Echocardiography in Measuring Left Ventricular Volumes and Ejection Fraction. Journal of the American College of Cardiology. 2012;59 (20):1799–808. DOI: 10.1016/j.jacc.2012.01.037

20. Leong SL, Chaiyakunapruk N, Lee SWH. Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Scientific Reports. 2017;7 (1):39. DOI: 10.1038/s41598-017-00075-1

21. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging. 2014;15 (10):1063–93. DOI: 10.1093/ehjci/jeu192

22. Dumont P, Leu JI-J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics. 2003;33 (3):357–65. DOI: 10.1038/ng1093